U.S. Markets closed
  • S&P 500

    3,951.57
    +34.93 (+0.89%)
     
  • Dow 30

    32,244.58
    +382.60 (+1.20%)
     
  • Nasdaq

    11,675.54
    +45.02 (+0.39%)
     
  • Russell 2000

    1,744.99
    +19.10 (+1.11%)
     
  • Crude Oil

    67.50
    +0.76 (+1.14%)
     
  • Gold

    1,982.70
    +9.20 (+0.47%)
     
  • Silver

    22.66
    +0.19 (+0.86%)
     
  • EUR/USD

    1.0728
    +0.0057 (+0.5364%)
     
  • 10-Yr Bond

    3.4810
    +0.0860 (+2.53%)
     
  • Vix

    24.15
    -1.36 (-5.33%)
     
  • GBP/USD

    1.2274
    +0.0100 (+0.8199%)
     
  • USD/JPY

    131.3880
    -0.4150 (-0.3149%)
     
  • BTC-USD

    27,973.30
    -82.98 (-0.30%)
     
  • CMC Crypto 200

    606.92
    +7.26 (+1.21%)
     
  • FTSE 100

    7,403.85
    +68.45 (+0.93%)
     
  • Nikkei 225

    26,945.67
    -388.12 (-1.42%)
     

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?

Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Is Abbott a bad-news buy that could turn things around in 2023, or has this once-safe healthcare stock become too risky of an investment to be holding right now? Last month, Abbott reported its fourth-quarter and year-end results for 2022.